zenocutuzumab

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
  Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.
  biopharma_dive · 4mo ago
• Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT
  R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.
  onclive · 4mo ago
• Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection
  In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma.
  onclive · 4mo ago
• RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice
  Learn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.
  onclive · 4mo ago
• Expanding ctDNA Applications to RCC and Germ Cell Tumors
  Experts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.
  onclive · 4mo ago
• Institutional Perspectives on Treatment Thresholds in PLGG
  Experts weigh PLGG treatment choices, balancing chemo and MEK inhibitors, guided by vision decline, symptoms, tumor growth, and family logistics.
  onclive · 4mo ago
• Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups
  In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians approach treatment selection in renal cell carcinoma across different IMDC…
  onclive · 4mo ago
• ctDNA in Metastatic Urothelial Carcinoma
  Experts explain how ctDNA tracking in metastatic cancer helps tailor immunotherapy, spot relapse early, and guide dose breaks—plus key limitations.
  onclive · 4mo ago
• Five Under 5: Top Oncology Videos for the Week of 5/3
  The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.
  onclive · 4mo ago
• The OncFive: Top Oncology Articles for the Week of 5/3
  The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.
  onclive · 4mo ago